A General Review Article on Study of Pilot Plant Scale-Up Problems in Tablet Formulation

Abstract

Scale-up in tablet manufacturing serves as an essential bridge between laboratory development and commercial production. During this transition, numerous challenges arise that can influence product quality, process reproducibility, and regulatory compliance. Common difficulties include variations in blending efficiency, granulation behavior, powder flow dynamics, compression characteristics, and resulting tablet properties such as hardness and friability [1][2]. Equipment design differences, altered process parameters, and changes in environmental conditions often cause deviations in critical quality attributes (CQAs), including dissolution, uniformity, and mechanical strength [2][3]. To address these issues, the application of Quality by Design (QbD), risk-based assessment, design of experiments (DoE), and Process Analytical Technology (PAT) is increasingly recommended [3][4]. Effective process validation and strong communication between formulation scientists and production personnel further support a successful scale-up pathway [5].

Introduction

Pilot plant scale-up is a critical stage in pharmaceutical tablet development, where a laboratory-optimized formulation is transitioned to larger batch sizes suitable for commercial production. This process ensures consistent quality, safety, and therapeutic performance while addressing challenges caused by changes in equipment, batch size, mixing dynamics, and environmental factors. Key tablet attributes affected include hardness, disintegration time, dissolution, content uniformity, and overall stability.

Advantages of Early Problem Identification during Scale-Up:

• Ensures consistent product quality and therapeutic efficacy.

• Improves process robustness and reliability.

• Reduces batch failures, rework, and costs.

• Supports regulatory compliance with validated processes.

• Optimizes critical process parameters (blending, granulation, compression).

• Enables accurate prediction and smooth commercial-scale transfer.

• Minimizes technical and processing risks.

Applications in Pilot Plant Work:

• Determining critical quality attributes (CQAs).

• Evaluating drug–excipient compatibility.

• Optimizing granulation, blending, and compression parameters.

• Assessing equipment performance and environmental effects.

• Implementing Process Analytical Technology (PAT) for real-time monitoring.

Common Scale-Up Challenges:

1. Formulation-related: drug–excipient incompatibility, particle size variability, moisture sensitivity.

2. Process-related: granulation issues, poor mixing, uneven drying.

3. Equipment-related: compression force variation, geometry differences, shear and speed effects.

4. Stability-related: thermal stress, humidity exposure.

5. Quality control: batch-to-batch variability, validation complexity.

Key Specific Issues:

• Content Uniformity: Segregation due to particle size, density differences, inefficient mixing, and material flow can lead to variable API distribution, impacting safety, efficacy, and regulatory compliance.

• Compression Defects: Capping and lamination arise from improper compression force, dwell time, particle size, moisture, or binder distribution. Mitigation involves optimizing compression parameters, granule size, moisture content, and binder uniformity.

• Binder Distribution Variability: Uneven binder leads to weak granules, inconsistent tablet hardness, friability, and disintegration; resolved via optimized granulation design, DoE, PAT monitoring, and post-blending strategies.

• Heat and Moisture Transfer Issues: Large batches and equipment differences can cause uneven drying, moisture retention, or overheating, resulting in flow issues, compression defects, or chemical degradation. Solutions include optimized drying parameters, advanced dryers, PAT sensors, and multi-point sampling.

Conclusion

The study of pilot plant scale-up in tablet formulation highlights the complex challenges encountered when transitioning from laboratory-scale development to full-scale commercial manufacturing. Success depends on a comprehensive understanding of the physicochemical properties of the API and excipients, as well as the influence of equipment design and process parameters [48]. Major challenges include maintaining uniform blending, optimizing granulation conditions, and achieving consistent tablet hardness and dissolution across all batch sizes [49]. The integration of Quality by Design (QbD), risk-based approaches, and the use of Process Analytical Technology (PAT) offers a systematic framework for identifying and controlling Critical Process Parameters (CPPs) and ensuring product quality [50,51]. Adherence to regulatory guidelines such as ICH Q8 further strengthens process reliability and compliance [52]. Future advancements in automation, continuous manufacturing, and digital modeling will likely simplify scale-up procedures and enhance consistency, leading to safer, more efficient pharmaceutical production systems.

References

[1] Allen LV, Popovich NG, Ansel HC. Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems. 9th ed. Lippincott Williams & Wilkins; 2011. [2] Gupta RC, Mazumder R, Kumar T. Manufacturing and Scale-Up Challenges for Solid Dosage Forms. Pharmaceutics. 2017;9(4):50. [3] Singh B, Kumar R, Ahuja N. Optimizing drug delivery systems using systematic \"design of experiments.\" Part I: Fundamental aspects. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2005;22(1):27–105. [4] U.S. Food and Drug Administration (FDA). Guidance for Industry: Process Validation: General Principles and Practices. 2011. [5] Kwon JH, et al. Scale-up of pharmaceutical solid dosage forms. Journal of Pharmaceutical Sciences. 2018;107(1):18–27. [6] Aulton, M. E., & Taylor, K. (Eds.). (2017). Aulton\'s Pharmaceutics: The Design and Manufacture of Medicines (5th ed.). Elsevier Health Sciences. [7] ISO 9001:2015. (2015). Quality Management Systems – Requirements. International Organization for Standardization. [8] Nguyen, T. T., & Byrn, S. R. (2013). Scale-up of Pharmaceutical Manufacturing Processes. Journal of Pharmaceutical Sciences, 102(10), 3515–3529. [9] Gamble, J. F., & Chiu, W. (2020). Scale-up Issues for Solid Oral Dosage Forms. In: Qiu, Y. et al. (Eds.), Developing Solid Oral Dosage Forms (2nd ed.). Academic Press [10] Shargel, L., & Yu, A. B. C. (2015). Applied Biopharmaceutics & Pharmacokinetics. McGraw-Hill. [11] Avachat, A. M., & Phadatare, A. G. (2014). “Design and Development of Pilot Plant for Tablet Formulation.” Journal of Advanced Pharmaceutical Technology & Research. [12] Porter, S. C. (2007). “Tablet Formulation and Scale-Up: Challenges and Solutions.” Pharmaceutical Technology. [13] FDA Guidance for Industry (2010). Scale-Up and Post-Approval Changes (SUPAC) for Immediate Release Solid Oral Dosage Forms. [14] Singh, P., et al. \"Critical Quality Attributes in Tablet Formulation.\" Journal of Pharmaceutical Sciences (2019). [15] Allen, L.V. \"Drug-Excipient Incompatibility in Solid Dosage Forms.\" American Journal of Health-System Pharmacy (2015). [16] Patel, M.N. \"Granulation Process Optimization in Scale-Up.\" International Journal of Pharmaceutics (2017). [17] Rathore, A.S. \"Scale-Up Challenges in Pharmaceutical Manufacturing.\" Pharmaceutical Technology (2018). [18] Sharma, V., & Awasthi, R. \"Content Uniformity During Scale-Up.\" Pharma Times (2020). [19] FDA. “PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance.” Guidance Document (2004). [20] Carr, R. \"Tablet Compression Troubleshooting Guide.\" Pharmaceutical Development and Technology (2016). [21] Lachman, L., et al. “The Theory and Practice of Industrial Pharmacy.” 4th Edition (2013). [22] Lachman, L., Lieberman, H. A., & Kanig, J. L. The Theory and Practice of Industrial Pharmacy (3rd ed.). Varghese Publishing House. [23] Gad, S. C. Pharmaceutical Manufacturing Handbook: Production and Processes. Wiley-Interscience. [24] Gowthamarajan, K., & Singh, S. K. “Critical factors in the scale-up of pharmaceutical tablet granulation.” Asian Journal of Pharmaceutics, 4(2), 69–75. [25] Aulton, M. E. Pharmaceutics: The Science of Dosage Form Design (2nd ed.). Churchill Livingstone. [26] DeGrazio, F. “From formulation to final product: The development path in pharmaceutical scale-up.” Pharmaceutical Technology Europe (2009). [27] Lachman, L., Lieberman, H. A., & Kanig, J. L. (1986). The Theory and Practice of Industrial Pharmacy (3rd ed.). Varghese Publishing House. [28] Gad, S. C. (2008). Pharmaceutical Manufacturing Handbook: Production and Processes. Wiley-Interscience. [29] Gowthamarajan, K., & Singh, S. K. (2010). “Critical factors in the scale-up of pharmaceutical tablet granulation.” Asian Journal of Pharmaceutics, 4(2), 71–77. [30] Aulton, M. E., & Taylor, K. M. G. (2018). Aulton’s Pharmaceutics: The Design and Manufacture of Medicines (5th ed.). Elsevier Health Sciences. [31] ANSEL, H. C., POPOVICH, N. G., & ALLEN, L. V. (2011). Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems (9th ed.). Lippincott Williams & Wilkins. [32] Yu, L.X., et al. Quality by Design (QbD) and Process Analytical Technology (PAT) in Pharmaceutical Manufacturing. Pharmaceutical Research, 2014. [33] Rathore, A.S. & Winkle, H. Quality by Design for Biopharmaceuticals: Principles and Case Studies. Nature Biotechnology, 2009. [34] Lakerveld, R. Digital Twins and Process Modeling for Continuous Pharmaceutical Manufacturing. Processes, 2020. [35] Lee, S.L., et al. Modernizing Pharmaceutical Manufacturing: Continuous Manufacturing and Process Intensification. Journal of Pharmaceutical Innovation, 2015. [36] Iveson, S.M., et al. Powder Technology and Advanced Material Characterization in Tablet Manufacturing. Powder Technology, 2017. [37] Yu LX. Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control. J Pharm Sci. [38] Lee SL et al. Modernizing Pharmaceutical Manufacturing: Continuous Manufacturing and Process Control. Int J Pharm. [39] Escotet MA et al. Digital Twins and AI-Driven Optimization in Pharmaceutical Manufacturing. Pharmaceutics. [40] Parikh D. Handbook of Pharmaceutical Granulation Technology. CRC Press. [41] Rubinstein MH & Cole G. Pharmaceutical Manufacturing and the Environment. Drug Dev Ind Pharm. [42] Alves, A. R., et al. (2024). A review on the scale-up of high-shear wet granulation processes and the impact of process parameters. ScienceDirect. [43] Jang, E. H., et al. (2020). Model-based scale-up methodologies for pharmaceutical granulation. Pharmaceutics. [44] Plath, T., et al. (2021). Parametric study of residence time distributions and their effect on granulation kinetics. International Journal of Pharmaceutics. [45] Zhao, J., et al. (2025). Development of a rapid method for residence time distribution measurement in continuous granulation. Pharmaceutics/MDPI. [46] U.S. Food and Drug Administration. (2020). SUPAC-IR: Scale-up and Post-approval Changes for Immediate-Release Solid Oral Dosage Forms — Guidance for Industry. [47] ICH. (2009/2017). Q8(R2) Pharmaceutical Development. ICH Harmonised Guideline. [48] Gupta, A., & Sharma, A. (2018). Role of Pilot Plant in Pharmaceutical Development. Journal of Pharmaceutical Sciences, 107(1), 12–24. [49] Lachman, L., Lieberman, H. A., & Kanig, J. L. (2008). The Theory and Practice of Industrial Pharmacy (3rd ed.). Varghese Publishing House. pp. 421–439. [50] Nasr, M. M. (2006). Quality by design (QbD): A modern approach to pharmaceutical quality. Pharmaceutical Technology, 30(10), 68–74. [51] Kawasaki, S. (2019). Scale-up considerations for pharmaceutical manufacturing. Journal of Drug Delivery Science and Technology, 52, 526–533. [52] ICH Guideline Q8 (R2). (2009). Pharmaceutical Development. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.

Copyright

Copyright © 2025 Mubeen Ahmad Mohammad Aarif, Darshana Pradip Dhamne, Vishakha Kailas Chaudhari. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.